Adlyxin is a prescription drug approved by the Food and Drug Administration (FDA) to improve glycemic control in adults with type 2 diabetes. Adlyxin is considered an adjunct treatment to diet and exercise. Adlyxin is also referred to by its drug name, Lixisenatide.
Adlyxin is an incretin mimetic. Adlyxin is also a glucagon-like peptide-1 (GLP-1) receptor agonist. Adlyxin is believed to work by mimicking the effects of incretin, which signals the pancreas to make more insulin and prevents the liver from releasing glucose.
How do I take it?
Prescribing information states that Adlyxin should be administered via a subcutaneous injection once a day.
Adlyxin comes as a prefilled pen.
The FDA-approved label for Adlyxin lists common side effects including headache, dizziness, hypoglycemia (low blood glucose), nausea, diarrhea, and vomiting.
Rare but serious side effects listed for Adlyxin include pancreatitis, kidney damage, and systemic allergic reactions.
For more details about this treatment, visit:
Adlyxin highlights of prescribing information (PDF) – Sanofi
We never share your personal information with anyone.